Hemophilia Inhibitor Genetics Study (HIGS)

Status Completed

Clinical Trial Summary

Several non-genetic and genetic factors that could influence the risk of inhibitor development in hemophilia A have been discussed but not fully explored. The aim of the HIGS is to identify these genetic factors.

Clinical Trial Description

The objective of the HIGS is to determine host genetic factors, other than mutations within the factor VIII gene, that are associated with the development of inhibitors in severe hemophilia A and response to antigenic challenge by factor VIII. The study will involve three phases, enrolling family groups composed of brother pairs and their parents (Phase I) and siblings, a family group composed of a person with severe hemophilia and his parents (Phase II), and a group of unrelated people with severe hemophilia for the purpose of confirming associations identified in Phases I and II. ;

Study Design

Observational Model: Family-Based

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00166387
Study type	Observational
Source	Skane University Hospital
Contact
Status	Completed
Phase	N/A
Start date	April 2003
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06320626` - Pharmacokinetic-guided Dosing of Emicizumab	Phase 4
Completed	`NCT04072237` - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia	Phase 1
Not yet recruiting	`NCT02554526` - Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors	N/A
Completed	`NCT03818529` - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Active, not recruiting	`NCT03619863` - ATHN 7: Hemophilia Natural History Study
Recruiting	`NCT06010953` - SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment	Phase 1/Phase 2
Completed	`NCT03951103` - rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A
Recruiting	`NCT05888870` - ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor	Phase 4
Terminated	`NCT04303572` - The Hemophilia Inhibitor Eradication Trial	Phase 3
Terminated	`NCT04489537` - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B	Phase 3
Terminated	`NCT04548791` - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders	Phase 1/Phase 2
Completed	`NCT06357572` - Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem
Recruiting	`NCT04647227` - SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors	Phase 4
Completed	`NCT03372993` - Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
Terminated	`NCT03204539` - INdividualized ITI Based on Fviii(ATE) Protection by VWF	Phase 4
Active, not recruiting	`NCT04205175` - A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab	Phase 4
Recruiting	`NCT06312475` - Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors	Phase 3
Recruiting	`NCT03598725` - Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China	Phase 4
Completed	`NCT04723693` - An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families
Completed	`NCT04789954` - Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors	Early Phase 1